Proprietary Antibody Drug Conjugates
to target major cancers

ADC Therapeutics is developing a pipeline of proprietary Antibody Drug Conjugates (ADCs) for the treatment of both solid and hematological cancers.

Monoclonal antibodies specific to particular types of tumor cells are combined with a novel class of highly potent pyrrolobenzodiazepine (PBD)-based warheads to selectively kill cancer cells.

Selective targeting should mean fewer side effects for patients and avoids repair-related resistance in continued treatment faced by other anti-cancer products on the market.

Homepage